If you want to be in the know about what’s going on at our organization, you’ve come to the right place!
Be sure to check back regularly to get our latest news updates.
NHF will update this page as more statements become available.
Developing such a treatment would necessitate plasma donations from many people who have fully recovered from COVID-19, and whose blood contains antibodies that can fight the coronavirus.
NHF is seeking comments on draft ASH ISTH NHF WHF clinical practice guidelines on VWD Diagnosis & Management.
NHF and HFA are members of the American Plasma Users Coalition.
The FDA approval is for the treatment and control of bleeding episodes occurring in adults and adolescents 12 years of age and older with hemophilia A or B with inhibitors.
Having an adequate supply of treatment products at home is critical to achieve safe patient care and continuity of treatment.
On March 27th, experts from NHF answered your questions regarding changes in insurance in our townhall webinar: Insurance: Coping During COVID-19.
MASAC's latest set of recommendations cover the use and management of emicizumab, the latest products licensed to treat bleeding disorders, integrating the CDC's opioid prescribing guidelines into bleeding disorders care, and bleeding prophylaxis for patients undergoing gastrointestinal endoscopies.
On March 20th, NHF’s President and CEO answered your questions about how COVID-19 affects our community.
Information and techniques you and your family can use to stay healthy during the COVID-19 pandemic.
Do you have questions regarding insurance coverage in light of the COVID-19 pandemic? We're here to help.
The halted trials were investigating concizumab prophylaxis treatment in hemophilia A and B patients regardless of inhibitor status.
NHF will update this page as more statements about product supply becomes available.
A statement from Dr. Valentino addressing the concerns of the community regarding the rapidly evolving COVID-19 situation.
Takeda responded to the HFA-NHF letter late yesterday regarding the recall of two lots of VONVENDI von Willebrand factor.
The National Hemophilia Foundation will continue to monitor the rapidly changing situation regarding COVID-19 and provide regular updates to our community.
XINITY® is currently indicated for the control and prevention of bleeding episodes and for perioperative management in adults and children, 12 years of age or older, with hemophilia B.
More than 400 people affected by bleeding disorders asked their legislators to take action on the Hemophilia SNF Access Act
We will provide updated guidance if new information has implication for the bleeding disorders community.
On February 28th, Genentech released a statement relating to the supply of Hemlibra as it relates to 2019-nCoV (novel coronavirus).
On February 27th, HFA and NHF submitted a letter to Takeda focusing on preliminary questions regarding the recall.
HFA and NHF recognize that recalls can be unsettling for many in the bleeding disorders community. We are in communications with Takeda to obtain additional detailed and timely information.